CAS NO: | 81131-70-6 |
规格: | ≥98% |
包装 | 价格(元) |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
1g | 电议 |
Molecular Weight (MW) | 446.51 |
---|---|
Formula | C23H35O7.Na |
CAS No. | 85956-22-5 (lactone); 81131-70-6 (sodium); 81093-37-0 (free acid); |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: 89 mg/mL (199.3 mM) |
Water: 89 mg/mL (199.3 mM) | |
Ethanol: 12 mg/mL (26.9 mM) | |
Solubility (In vivo) | CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)[O-])O)O)O.[Na+] |
Synonyms | Apotex; CS-514 Sodium, Pravachol; Pravaselect; Apo-Pravastatin; Mevalotin; Elisor; Lipostat; Pravastatin Sodium; Aventis; Bristacol; CS 514; CS-514; CS514; Chemical Name: sodium;(3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoate SMILES Code: CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)[O-])O)O)O.[Na+] |
In Vitro | In vitro activity: Pravastatin-Na at 10 μM inhibits the sterol synthesis at a level greater than 50% in PBMC. Pravastatin produces relaxation of isolated aortic rings, with maximum vasorelaxations of 62.8% at 10 μM and latency of ~8 min. Pravastatin (< 10 μM) stimulates NOS activity and NO release within 10 min in cultured bovine aortic endothelial cells. L-arginine potentiates NO production in response to Pravastatin (< 10 μM) in cultured bovine aortic endothelial cells. Pravastatin results in a dose-dependent inhibition of macrophage cholesterol synthesis in human monocyte derived macrophages(HMDM), mouse peritoneal macrophages (MPM) and a J-774 A.1 macrophagelike cell lines. Small concentrations of pravastatin (< 0.19 μg/mL) increases the cellular cholesterol esterification rate after incubation with LDL, but higher concentrations (< 100 μg/mL) results in an inhibition of the esterification. Pravastatin (< 0.5 mM) decreases Rho/ROCK pathway activity in human colon and ileum explants, which leads to decreased CCN2 mRNA levels. Pravastatin (<1 mM) also induces CCN2 inhibition in primary human smooth muscle cells. Pravastatin (< 0.5 mM) decreases type I collagen and fibronectin mRNA levels in both human colon and ileum explants and primary human smooth muscle cells. |
---|---|
In Vivo | Pravastatin (40 mg, single dose) causes a reduction in cholesterol synthesis in human monocyte derived macrophages by 62% in healthy subjects and 47% in hypercholesterolaemic patients. Pravastatin (40 mg/day, 8 weeks) results in a 55% inhibition of cholesterol synthesis and a 57% increase in LDL degradation in hypercholesterolaemic patients. Pravastatin (30 mg/kg/d) results in decreased length of the dystrophic lesions by 34% and recovery of muscular structure in Male Wistar rats receiving irradiation, associated with decreased CCN2 level. |
Animal model | Male Wistar rats receiving irradiation for 5 weeks |
Formulation & Dosage | Dissolved in water; 30 mg/kg/day; oral administration |
References | Immunopharmacology. 1996 Aug;34(1):51-61; Br J Clin Pharmacol. 1994 Dec;38(6):513-9; Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5331-40. |